Identifying patients who benefit more from perioperative immunotherapy combinations for resectable non-small cell lung cancer based on clinical and molecular characteristics: a meta-analysis of randomized clinical trials.
Yunchang MengHedong HanSuhua ZhuChuling LiHuijuan LiZhaofeng WangRanpu WuYimin WangQingfeng ZhangYanzhuo GongYong SongTangfeng LvHongbing LiuPublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2024)
Perioperative IO-CT is more effective but more toxic than CT alone in resectable NSCLC. Patients with PD-L1 ≥ 1%, squamous NSCLC, a history of smoking, age < 65 years and male gender may experience greater benefits from perioperative IO-CT.
Keyphrases
- image quality
- dual energy
- computed tomography
- cardiac surgery
- contrast enhanced
- patients undergoing
- small cell lung cancer
- positron emission tomography
- advanced non small cell lung cancer
- locally advanced
- magnetic resonance imaging
- mental health
- acute kidney injury
- squamous cell carcinoma
- magnetic resonance
- clinical trial
- smoking cessation
- brain metastases